Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC

Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to chemotherapy in the first line setting in patients harboring an EGFR mutation in th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment and research communications 2017, Vol.11, p.10-16
Main Authors: Melosky, Barb, Sheffield, Brandon S., Tsou, Mei-Hua, Gagne, S. Eric, Ionescu (Naus), Diana N., Yang, James Chih-Hsin
Format: Article
Language:English
Subjects:
Afatinib
EGFR mutation
Erlotinib
Gefitinib
Non-small cell lung cancer
NSCLC
TKI, Case study
Tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to chemotherapy in the first line setting in patients harboring an EGFR mutation in the EURTAC [1], IPASS [2], LUX-LUNG 3 [3] and LUX-LUNG 6 [4] trials. This article describes the case of a patient treated at a Cancer Centre in Taiwan and at the British Columbia Cancer Agency in Canada. This patient experienced a remarkable response to a number of different systemic treatments. Despite not having a detectable EGFR mutation, he had a positive and prolonged response to all three EGFR TKIs. This case challenges current treatment paradigms for the treatment of a NSCLC patient whose tumour does not have an activating EGFR mutation.
ISSN:2468-2942
2468-2942
DOI:10.1016/j.ctarc.2017.02.005